4D Molecular Therapeutics (FDMT) vs Iambic Therapeutics (IAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iambic Therapeutics is the larger company by market cap ($621.4 million vs $576.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | IAM |
|---|---|---|
| Share price | $10.23 | $13.11 |
| Market cap | $576.76M | $621.42M |
| 1-day change | -4.57% | -8.06% |
| YTD return | +36.40% | — |
| 1-year return | -5.63% | — |
| 5-year return | -53.61% | — |
| EPS (TTM) | $-2.70 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.21M | — |
| Revenue growth (YoY) | +230194.59% | — |
| Net income (latest FY) | $-140.11M | — |
| Operating margin | -187.24% | — |
| Net margin | -164.43% | — |
| 52-week high | $16.93 | $25.00 |
| 52-week low | $6.96 | $9.60 |
| Distance from 52-week high | -39.57% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +174.58% | +107.86% |
| Average volume | 967.00K | 714.92K |
| Shares outstanding | 56.38M | 47.40M |
| Employees | 196 | 171 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Iambic Therapeutics
IAM stock →Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees
FDMT vs IAM FAQ
Which is bigger, 4D Molecular Therapeutics or Iambic Therapeutics?
Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $576.76M for 4D Molecular Therapeutics (FDMT).
Are 4D Molecular Therapeutics and Iambic Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.